<?xml version="1.0" encoding="UTF-8"?>
<p>Elevated cardiac biomarkers have been identified in COVID-19 patients, especially in those with severe conditions. Of note, recent case reports highlighted cardiac involvement as a complication associated with COVID-19, even without respiratory symptoms [
 <xref rid="B30-jcm-09-01407" ref-type="bibr">30</xref>,
 <xref rid="B52-jcm-09-01407" ref-type="bibr">52</xref>]. Myocardial injury, defined as elevated cardiac biomarkers, was found in five of the first 41 patients (12%) with COVID-19 in Wuhan, which mainly manifested as an increase in high-sensitivity cardiac troponin I (hs-cTnI) levels (&gt;28 pg/mL) [
 <xref rid="B8-jcm-09-01407" ref-type="bibr">8</xref>]. In this study, the incidence was significantly higher in patients with ICU care than those without (31% vs. 4%, 
 <italic>p</italic> = 0.017).
</p>
